See more : Ziccum AB (publ) (ZICC.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Cortexyme, Inc. (CRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cortexyme, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rai Way S.p.A. (0R40.L) Income Statement Analysis – Financial Results
- VERBUND AG (OEZVY) Income Statement Analysis – Financial Results
- Iron Horse Acquisitions Corp. Common Stock (IROH) Income Statement Analysis – Financial Results
- Vydrotech, Inc. (VYDR) Income Statement Analysis – Financial Results
- Meganet Corporation (MGNT) Income Statement Analysis – Financial Results
Cortexyme, Inc. (CRTX)
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -90.32M | -78.89M | -39.17M | -11.47M | -10.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.95M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 373.00K | 2.04M | 2.19M | 600.00K | -222.00K |
| Net Income | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| EPS Diluted | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
Insider Weekends: Moderna Executives Go On A Selling Spree
Insider buying decreased significantly last week. Notable Insider Buys: Mercury General Corporation, Cortexyme, Inc., New Mountain Finance Corporation, Berkshir
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the first quarter 2020 and provided an update on its business. “The current...
Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it
Summit Financial Group Reports First Quarter 2020 Results
MOOREFIELD, W.V., April 30, 2020 -- Summit Financial Group, Inc. (“Company” or “Summit”) (NASDAQ: SMMF) today reported first quarter 2020 net income of $4.51 million, or $0.35.
During Ramadan, our ritual of gathering won’t happen but our values of community remain
This year, we plan on holding our prayers at home as a family and focusing on the blessings of health and wellness despite social distancing.
Cortexyme, Inc. (NASDAQ:CRTX) Position Increased by Bank of New York Mellon Corp
Bank of New York Mellon Corp boosted its holdings in Cortexyme, Inc. (NASDAQ:CRTX) by 180.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,867 shares of the...
Cortexyme, Inc. (NASDAQ:CRTX) Short Interest Up 16.9% in March
Cortexyme, Inc. (NASDAQ:CRTX) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,630,000 shares, a growth of 16.9% from the March 15th total of 1,393,800 shares. Currently, 13.8%...
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Cortexyme (CRTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elanco Animal Health (ELAN) and Cortexyme (CRTX). Elanco Animal Health
Cornerstone Christian has simple goal in Div. IV state girls basketbal semi: ‘Play our game’
No. 1-ranked Fort Loramie offers an imposing challenge in Thursday's 6 p.m. semifinal in Columbus.
Surprising Norton proves ‘anything can happen’; Who wins Division I at Canton? OHSAA girls basketball regional preview
By the end of the week, we'll know which Northeast Ohio girls basketball teams will be headed to Columbus for the OHSAA state semifinals in each division.
Source: https://incomestatements.info
Category: Stock Reports